The conversation discusses using 2-deoxy-d-ribose (2DDR) for hair regrowth, with users sharing mixed experiences and side effects like hair loss in new areas and increased anxiety. The original poster plans to continue testing and comparing it to minoxidil, noting potential instability in 2DDR formulations.
Replicel's results were delayed, but Shiseido might share data at BioJapan on October 11. Users are hopeful for new treatments like RCH-01, potentially eliminating the need for finasteride or minoxidil.
A product called "PP405 Hair Follicle Serum" is being sold on Shopee, claiming to cure baldness without clinical trials or FDA approval, but users are skeptical and refer to it as "snake oil." Some users discuss testing the product's contents, while others share their experiences with hair loss treatments like finasteride.
Hair loss treatments discussed include alfatradiol, big 3, finasteride, RU58841, and stemoxydine. Alfatradiol is less effective but has fewer side effects, and mixing with stemoxydine may improve results.
The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.
The conversation humorously discusses using a dermaroller for hair growth, with a playful suggestion of using it on the wrist. It includes references to Minoxidil, finasteride, and RU58841 as treatments.
Hair loss can be influenced by chronic low-level allergies, and treatments like fexofenadine or topical cetirizine may help with regrowth. The user avoids finasteride, dutasteride, and minoxidil, and has tried Regenera Activa and PRF sessions.
ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.
Pp405 is discussed as a potential hair loss treatment, with humorous suggestions about rectal administration for increased effectiveness. Users joke about unconventional methods and express willingness to try anything for hair regrowth.
Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.
A user shared their 14-month progress using finasteride, minoxidil, and dermarolling for hair loss, showing before and after pictures. Replies included brief comments and a question about the user's identity.
The user is using finasteride, HGH, GHK-CU, BPC-157, KPV, biotin/collagen/keratin vitamins, ketoconazole shampoo, and low-dose naltrexone to address hair loss, avoiding minoxidil due to past shedding experiences. Adenosine is discussed as a potential alternative to minoxidil, though it is noted to be expensive and hard to find.
Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.
Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Users question effectiveness of HMI-115 and consider waiting longer for results.
The conversation is about someone planning to start finasteride for hair loss and wanting to interpret pre-treatment blood panels to assess the risk of side effects like gynecomastia. They list various tests to measure hormone levels and other health indicators.
A user shared their experience using RU58841, Minoxidil, and Finasteride for hair loss, noting good results but increased acne from RU58841. They plan to replace RU58841 with Finasteride while continuing Minoxidil.
Results for PP405 are expected next year, with concerns about its pricing and potential black market availability. Some users believe it may be slightly more effective than finasteride and dutasteride, and combining it with treatments like minoxidil and microneedling could be beneficial.
Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.
The user is seeking advice on adding CB 03-01 to their hair loss treatment, which includes RU58841, Fluridil, Minoxidil, and Pantostin, but cannot use finasteride.
The conversation discusses a user's plan to inject NAD+ and GHK-Cu into their scalp to improve hair health, with concerns raised about the risks of infection and necrosis. Alternatives like finasteride, dutasteride, microneedling, oral minoxidil, and scalp massages are suggested.
The conversation is about comparing the effectiveness of 5% RU58841 and 0.5% pyrilutamide for hair loss treatment. The user is asking if the higher concentration of RU58841 makes it stronger than the lower dose of pyrilutamide.
Post Finasteride Syndrome (PFS) may result from epigenetic changes and gut microbiota alterations. Supplementing with Allopregnanolone might protect against these adverse effects.
The conversation is about the effectiveness and safety of a hair loss treatment called Pyri, with users discussing its availability and comparing it to other treatments like RU58841, fluridil, and alfatradiol. Some users are waiting for FDA approval before using Pyri, while others share their positive experiences with RU58841 and suggest additional treatments with minimal side effects.
The user is considering switching from finasteride and RU58841 to dutasteride due to ongoing hair loss concerns. They are unsure if the hair loss is due to shedding or worsening condition.
A 27-year-old male experiencing hair loss at Norwood 3 level has tried minoxidil and finasteride but stopped finasteride due to side effects. He is exploring alternatives like Dermapen, Regenepure DR Shampoo, saw palmetto, and considering aromatase inhibitors for managing side effects, while also seeking advice on DHT blockers.